AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2722724 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmetazole
Number of subjects: 0
Study 2722724 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 0
Study 31702802 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimodal release ondansetron (6 mg immediate release and 18 mg 24-hour release, total 24 mg)
Number of subjects: 321
Study 31702802 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimodal release ondansetron
Number of subjects: 321
Study 31702802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study 28229892 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicinumab (100 mg/kg intravenously once every 4 weeks for six doses)
Number of subjects: 82
Study 28229892 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenously once every 4 weeks for six doses)
Number of subjects: 82
Study 26608440 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment program (MAGIC)
Number of subjects: 65
Study 26608440 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical care
Number of subjects: 65
Study 23116775 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (ferrous sulfate, 10 mg of elemental iron per day)
Number of subjects: 53
Study 23116775 — intervention group
Group type: COMPARATOR
Intervention: Control (no iron supplementation)
Number of subjects: 53
Study 21349218 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg) + Mebendazole (500 mg)
Number of subjects: 82
Study 21349218 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel (40 mg/kg) alone
Number of subjects: 82
Study 19346844 — intervention group
Group type: COMPARATOR
Intervention: Intravenous beta-blocker (landiolol hydrochloride, mean dose of 0.032 mg/kg per minute)
Number of subjects: 60
Study 19346844 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of intravenous beta-blocker and sublingual NTG (0.3 mg)
Number of subjects: 60
Study 16689997 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermographic imaging during temperature provocation (cooling and warming)
Number of subjects: 12
Study 16689997 — intervention group
Group type: COMPARATOR
Intervention: Thermographic imaging during static measurement at room temperature
Number of subjects: 12
Study 16689997 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermographic imaging during cold and warm temperature challenges
Number of subjects: 12
Study 15298609 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication therapy
Number of subjects: 164
Study 15298609 — intervention group
Group type: COMPARATOR
Intervention: Non-eradicated group
Number of subjects: 164
Study 15298609 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmoking group post-eradication
Number of subjects: 164
Study 15298609 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking group post-eradication
Number of subjects: 164
Study 11304056 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg/kg over 48 hours)
Number of subjects: 54
Study 11304056 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine (8 mg/kg, 3 doses)
Number of subjects: 54
Study 8869511 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (not specified)
Number of subjects: 617
Study 1505554 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation (R) group
Number of subjects: 171
Study 1505554 — intervention group
Group type: COMPARATOR
Intervention: Reference, hospital-based treatment (H) group
Number of subjects: 171
Study 6320360 — intervention group
Group type: EXPERIMENTAL
Intervention: co-trimoxazole
Number of subjects: 52
Study 6320360 — intervention group
Group type: EXPERIMENTAL
Intervention: pivmecillinam/pivampicillin
Number of subjects: 52
Study 31604428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.25μg/kg) added to ropivacaine
Number of subjects: 125
Study 31604428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.50μg/kg) added to ropivacaine
Number of subjects: 125
Study 31604428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0μg/kg) added to ropivacaine
Number of subjects: 125
Study 31604428 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine alone (without dexmedetomidine)
Number of subjects: 125
Study 28772281 — intervention group
Group type: EXPERIMENTAL
Intervention: Linsitinib 150 mg BID plus erlotinib 150 mg QD
Number of subjects: 205
Study 28772281 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus erlotinib 150 mg QD
Number of subjects: 205
Study 26964164 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint application therapy with bushentongyu plaster and tamsulosin hydrochloride (0.2 mg every night for 100 days)
Number of subjects: 50
Study 26964164 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin hydrochloride (0.2 mg every night for 100 days)
Number of subjects: 50
Study 23767986 — intervention group
Group type: COMPARATOR
Intervention: 1 mg daily oral rasagiline (monotherapy)
Number of subjects: 0
Study 23767986 — intervention group
Group type: COMPARATOR
Intervention: 1 mg daily oral rasagiline (adjunct therapy with levodopa)
Number of subjects: 0
Study 23767986 — intervention group
Group type: COMPARATOR
Intervention: 1 mg daily oral rasagiline (adjunct therapy)
Number of subjects: 0
Study 21285525 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-stretching and soft tissue TrP manual therapy (Str-ST)
Number of subjects: 60
Study 21285525 — intervention group
Group type: COMPARATOR
Intervention: Self-stretching (Str)
Number of subjects: 60
Study 19880463 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment with selective serotonin reuptake inhibitors
Number of subjects: 0
Study 19880463 — intervention group
Group type: EXPERIMENTAL
Intervention: One-year treatment continuation
Number of subjects: 0
Study 16289979 — intervention group
Group type: EXPERIMENTAL
Intervention: DAG meal
Number of subjects: 13
Study 16289979 — intervention group
Group type: COMPARATOR
Intervention: TAG meal
Number of subjects: 13
Study 15851173 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular programmed electrical stimulation (BV-PES)
Number of subjects: 18
Study 15851173 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular programmed electrical stimulation (RV-PES)
Number of subjects: 18
Study 11054616 — intervention group
Group type: COMPARATOR
Intervention: Tirofiban
Number of subjects: 4750
Study 9172085 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 131
Study 9172085 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated
Number of subjects: 131
Study 1426866 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth
Number of subjects: 84
Study 1426866 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth plus antibiotics
Number of subjects: 84
Study 1426866 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 84
Study 1426866 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradicated
Number of subjects: 84
Study 1426866 — intervention group
Group type: COMPARATOR
Intervention: H. pylori not eradicated
Number of subjects: 84
Study 3913728 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 431
Study 3913728 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 431
Study 3913728 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin and Control
Number of subjects: 431
Study 3304625 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive course of chemotherapy consisting of vincristine, procarbazine and methotrexate, followed by citrovorum factor rescue
Number of subjects: 350
Study 3304625 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced radiotherapy to CNS areas outside the primary tumour site by 10 Gy
Number of subjects: 350
Study 29022212 — intervention group
Group type: EXPERIMENTAL
Intervention: Saroglitazar magnesium 4-mg tablet under fed conditions (high-calorie and high-fat breakfast)
Number of subjects: 54
Study 29022212 — intervention group
Group type: COMPARATOR
Intervention: Saroglitazar magnesium 4-mg tablet under fasting conditions
Number of subjects: 54
Study 27054695 — intervention group
Group type: EXPERIMENTAL
Intervention: CRAE (central retinal artery equivalent) measurement
Number of subjects: 440
Study 27054695 — intervention group
Group type: EXPERIMENTAL
Intervention: CRVE (central retinal vein equivalent) measurement
Number of subjects: 440
Study 27054695 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of CRAE with macular ganglion cell layer thickness
Number of subjects: 440
Study 27054695 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of CRVE with macular retinal thickness
Number of subjects: 440
Study 27054695 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of CRVE with retinal nerve fibre layer thickness at the optic disc
Number of subjects: 440
Study 24727897 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation in a shortened position (CT)
Number of subjects: 15
Study 24727897 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation in a neutral position (nCT)
Number of subjects: 15
Study 24727897 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 15
Study 23672318 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (0.25 mg/kg bupivacaine 0.5%)
Number of subjects: 100
Study 23672318 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 100
Study 20578393 — intervention group
Group type: EXPERIMENTAL
Intervention: Explanatory clinical trials
Number of subjects: 0
Study 20578393 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic clinical trials
Number of subjects: 0
Study 18793342 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 30 mg
Number of subjects: 10
Study 18793342 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 40 mg
Number of subjects: 10
Study 18793342 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 20 mg
Number of subjects: 10
Study 18793342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 18793342 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 5 mg
Number of subjects: 10
Study 18793342 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg
Number of subjects: 10
Study 16884504 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed Ventricular Pacing (MVP) mode
Number of subjects: 129
Study 16884504 — intervention group
Group type: COMPARATOR
Intervention: DDD/R mode
Number of subjects: 129
Study 16884504 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed Ventricular Pacing (MVP) mode in patients with SND
Number of subjects: 129
Study 16884504 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed Ventricular Pacing (MVP) mode in patients with AVB
Number of subjects: 129
Study 12591053 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (800 IU) and Vitamin C (1000 mg) supplementation
Number of subjects: 57
Study 12591053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 10943585 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic agent (urokinase or streptokinase), n = 12
Number of subjects: 40
Study 10943585 — intervention group
Group type: COMPARATOR
Intervention: Heparin, n = 11
Number of subjects: 40
Study 8765432 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT plus leucovorin (30 mg/day)
Number of subjects: 26
Study 8765432 — intervention group
Group type: COMPARATOR
Intervention: UFT alone (400 mg/day)
Number of subjects: 26
Study 2013559 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen treatment
Number of subjects: 30
Study 2013559 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 normal volunteers)
Number of subjects: 30
Study 6148878 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 80 mg/day
Number of subjects: 48
Study 6148878 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 160 mg/day
Number of subjects: 48
Study 6148878 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg/day
Number of subjects: 48
Study 6148878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 30876431 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA for 30 s) combined with upper limb physical therapy (20 min passive movement + 20 min active mini-bike) for 10 sessions.
Number of subjects: 0
Study 30876431 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (current stimulation for 30 s) combined with upper limb physical therapy (20 min passive movement + 20 min active mini-bike) for 10 sessions.
Number of subjects: 0
Study 30876431 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA) combined with upper limb physical therapy.
Number of subjects: 0
Study 30876431 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS combined with upper limb physical therapy.
Number of subjects: 0
Study 29944604 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone ester (KE) supplement (750 mg·kg)
Number of subjects: 11
Study 29944604 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 11
Study 27142443 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session group intervention
Number of subjects: 205
Study 27142443 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 205
Study 23707139 — intervention group
Group type: EXPERIMENTAL
Intervention: Weights (3 repetition‐maximum [RM] bench press and squat)
Number of subjects: 18
Study 23707139 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint (5 × 40 m)
Number of subjects: 18
Study 23707139 — intervention group
Group type: COMPARATOR
Intervention: Control (rested)
Number of subjects: 18
Study 22845718 — intervention group
Group type: EXPERIMENTAL
Intervention: Misgav Ladach technique (Group 1)
Number of subjects: 112
Study 22845718 — intervention group
Group type: COMPARATOR
Intervention: Traditional (Pfannenstiel) technique (Group 2)
Number of subjects: 112
Study 20927781 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0449 (hedgehog pathway inhibitor), once per day continuous therapy, oral administration
Number of subjects: 3
Study 18830041 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 16418556 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal breathing training using biofeedback (once a week for 4 weeks)
Number of subjects: 25
Study 11155152 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) at 3 MU thrice weekly (TIW) for 12 months
Number of subjects: 66
Study 11155152 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) at 6 MU TIW
Number of subjects: 66
Study 11155152 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) at 3 MU TIW
Number of subjects: 66
Study 11155152 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) in cirrhotic patients
Number of subjects: 66
Study 11155152 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) for acute hepatitis C
Number of subjects: 66
Study 9542555 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol 2 g
Number of subjects: 97
Study 9542555 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol + PCA morphine
Number of subjects: 97
Study 9542555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 7522977 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 micrograms.kg‐1 pentamorphone
Number of subjects: 64
Study 7522977 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram.kg‐1 pentamorphone
Number of subjects: 64
Study 7522977 — intervention group
Group type: COMPARATOR
Intervention: 5 micrograms.kg‐1 fentanyl
Number of subjects: 64
Study 7522977 — intervention group
Group type: COMPARATOR
Intervention: 7.5 micrograms.kg‐1 fentanyl
Number of subjects: 64
Study 3045033 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha 2 interferon
Number of subjects: 0
Study 3045033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31466693 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help modality intervention delivered by psychologists
Number of subjects: 84
Study 31466693 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified counsellor-led problem-solving intervention implemented by less experienced counsellors
Number of subjects: 84
Study 30648919 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV15 Formulation A
Number of subjects: 690
Study 30648919 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV15 Formulation B
Number of subjects: 690
Study 30648919 — intervention group
Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 690
Study 26967591 — intervention group
Group type: EXPERIMENTAL
Intervention: 18‐mmHg graduated stockings
Number of subjects: 40
Study 26967591 — intervention group
Group type: EXPERIMENTAL
Intervention: 23‐mmHg graduated stockings
Number of subjects: 40
Study 26967591 — intervention group
Group type: COMPARATOR
Intervention: No hosiery
Number of subjects: 40
Study 26054135 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion treatment applied to specific acupuncture points (Shenque, Zhongji, Guanyuan, Qihai, Zigong, Xuebai) for 3 sessions until transfer time.
Number of subjects: 114
Study 26054135 — intervention group
Group type: COMPARATOR
Intervention: Control group with no acupuncture and moxibustion intervention.
Number of subjects: 114
Study 26054135 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion treatment.
Number of subjects: 114
Study 23681030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone, 8 mg
Number of subjects: 328
Study 23681030 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 328
Study 21685111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal DEX 1 µg kg(‐1) (Group D)
Number of subjects: 60
Study 21685111 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group P)
Number of subjects: 60
Study 19214556 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine supplementation (6.4 g day(-1))
Number of subjects: 14
Study 19214556 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLG)
Number of subjects: 14
Study 17872930 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 30
Study 17872930 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study 15086482 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin synthesis measurement after serum albumin decline
Number of subjects: 79
Study 15086482 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of inflammatory markers (IL-6, CRP, alpha1AG, ceruloplasmin)
Number of subjects: 79
Study 15086482 — intervention group
Group type: EXPERIMENTAL
Intervention: Equilibrated normalized protein catabolic rate (enPCR) measurement
Number of subjects: 79
Study 15086482 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum albumin concentration measurement
Number of subjects: 79
Study 15086482 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis of all patients
Number of subjects: 79
Study 11471851 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary omeprazole (20 ‐ 40 mg/day depending on age) + metronidazole (30 ‐ 40 mg/kg per day) + amoxycillin (750 mg/day)
Number of subjects: 106
Study 11471851 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic omeprazole (20 ‐ 40 mg/day) + metronidazole (30 ‐ 40 mg/kg per day) + amoxycillin (750 mg/day)
Number of subjects: 106
Study 11471851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily) + metronidazole (30 ‐ 40 mg/kg per day) + amoxycillin (750 mg/day)
Number of subjects: 106
Study 9693998 — intervention group
Group type: EXPERIMENTAL
Intervention: Biographical Personality Interview (BPI)
Number of subjects: 179
Study 8163736 — intervention group
Group type: EXPERIMENTAL
Intervention: Starchy food products, 12-15 times a day, in addition to the normal diet
Number of subjects: 8
Study 8163736 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose products, 12-15 times a day, in addition to the normal diet
Number of subjects: 8
Study 8163736 — intervention group
Group type: COMPARATOR
Intervention: Control period (no addition of test products to the normal diet)
Number of subjects: 8
Study 8163736 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sucrose mouthrinse
Number of subjects: 8
Study 3170784 — intervention group
Group type: EXPERIMENTAL
Intervention: Sign-alone
Number of subjects: 60
Study 3170784 — intervention group
Group type: COMPARATOR
Intervention: Speech-alone
Number of subjects: 60
Study 3170784 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous communication
Number of subjects: 60
Study 3170784 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating between speech and sign
Number of subjects: 60
Study 28843588 — intervention group
Group type: EXPERIMENTAL
Intervention: High religiosity group listening to non-consensual kiss scenario
Number of subjects: 92
Study 28843588 — intervention group
Group type: EXPERIMENTAL
Intervention: Low religiosity group listening to non-consensual kiss scenario
Number of subjects: 92
Study 28843588 — intervention group
Group type: EXPERIMENTAL
Intervention: High religiosity group listening to consensual kiss scenario
Number of subjects: 92
Study 28843588 — intervention group
Group type: EXPERIMENTAL
Intervention: Low religiosity group listening to consensual kiss scenario
Number of subjects: 92
Study 28843588 — intervention group
Group type: COMPARATOR
Intervention: High religiosity group
Number of subjects: 92
Study 28843588 — intervention group
Group type: COMPARATOR
Intervention: Low religiosity group
Number of subjects: 92
Study 26395410 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 10
Study 26395410 — intervention group
Group type: COMPARATOR
Intervention: Operative treatment for femoral deformities
Number of subjects: 10
Study 26395410 — intervention group
Group type: COMPARATOR
Intervention: Operative treatment for acetabular deformities
Number of subjects: 10
Study 26395410 — intervention group
Group type: COMPARATOR
Intervention: Labral refixation
Number of subjects: 10
Study 26395410 — intervention group
Group type: COMPARATOR
Intervention: Capsular closure
Number of subjects: 10
Study 26009922 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided bone regeneration (GBR) with recombinant human platelet‐derived growth factor‐BB (rhPDGF‐BB) incorporated into a beta‐tricalcium phosphate (β‐TCP)/hydroxyapatite (HA) carrier
Number of subjects: 30